Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Fintel reports that on March 28, 2025, B of A Securities upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Buy. Analyst Price Forecast Suggests 125.89% Upside As of March 19 ...

Beam Therapeutics Inc. (BEAM) shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

EDT Cathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics (BEAM) todayStay Ahead of the Market: Discover outperforming ...

Beam Therapeutics Inc.’s BEAM share price has dipped by 11.15%, which has investors questioning if this is right time to buy.

Key Insights Given the large stake in the stock by institutions, Beam Therapeutics' stock price might be vulnerable ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the ...

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

Verve Therapeutics, Inc.’s VERV share price has surged by 8.03%, which has investors questioning if this is right time to ...

Beam Therapeutics Inc. (BEAM) shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...